Congress studies cannabis legalization with criminal justice reform at center
S. 3576 — PREPARE Act of 2025 · Filed by John Hickenlooper (D-CO) · Introduced Dec 18, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a federal Commission on Cannabis Regulation tasked with studying how to transition from cannabis prohibition to a regulated legal framework modeled on alcohol regulation. The Commission will hold public hearings, solicit input from industry, criminal justice advocates, and state regulators, and deliver recommendations within one year on how to address barriers to legalization—including criminal justice reform, banking access for cannabis businesses, medical research, and product safety standards.
Why we flagged it
The bill's core function is establishing a deliberative commission to study a regulatory pathway for cannabis legalization, modeled on alcohol. It is not a legalization bill itself, but a procedural mechanism to gather evidence and recommendations for future legislative action.
What the text implies
- The commission's one-year timeline and explicit modeling on alcohol regulation suggests Congress may be preparing for rapid legalization legislation following the report, potentially bypassing extended debate.
- Inclusion of state cannabis regulators and multi-state operators on the commission may amplify industry influence over the regulatory framework design, potentially favoring larger operators over small/minority-owned businesses despite SBA representation.
- The bill's focus on 'prompt' legalization and the framing of prohibition as discriminatory may constrain the commission's ability to recommend cautious or phased approaches, narrowing the range of 'plausible' pathways studied.
- Federal agencies (ATF, NHTSA, FDA, IRS, etc.) are mandated to participate, but the commission has no rulemaking authority—creating a risk that recommendations are shelved or ignored if they conflict with agency interests or existing statutory constraints.
- The bill does not address interstate commerce or international trade frameworks, leaving major regulatory questions (cross-state sales, import/export) unresolved and potentially subject to future executive or judicial action.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill establishes a transparent, inclusive study process that centers criminal justice reform (particularly for minorities and veterans harmed by prohibition), medical access, and research—all documented public harms. It does not legalize cannabis unilaterally but creates a deliberative pathway with broad stakeholder input and no rulemaking authority, preserving congressional discretion. The commission's composition includes criminal justice advocates, formerly incarcerated individuals, and e
Who stands to gain
- cannabis cultivators and retailers (state-licensed operators)
- multi-state cannabis operators
- cannabis ancillary industries (testing, packaging, distribution)
- financial services (banking, insurance) seeking cannabis client access
- medical cannabis manufacturers and distributors
Named in the bill
Attorney General, Senate Majority Leader, Senate Minority Leader, House Majority Leader, House Minority Leader, Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), National Highway Traffic Safety Administration (NHTSA), Food and Drug Administration (FDA), Department of Agriculture, Department of Commerce, Department of Health and Human Services, National Institutes of Health — and 8 more
Where it stands
- Dec 18, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Dec 18, 2025 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $30,000 in lobbying spend. A filing names 14 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
John Hickenlooper, the sponsor, reported $975,352 in PAC receipts in the 2026 cycle.
- Students for Sensible Drug Policy — $30,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (14,801 characters) on Aug 12, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress studies cannabis legalization with criminal justice reform at center” QuorumCivic. https://share.quorumcivic.app/bill/119/s3576 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.